Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of Poseltinib in Healthy Subjects
NCT03099148Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of poseltinib in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Drug Concentration at 72 hours and Area Under the Concentration Versus Time Curve From Time Zero to Infinity at 72 hours. Started Apr 2017; status: completed.
02
Drugs
poseltinib
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03099148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03099148.